Pioglitazone ameliorates systolic and diastolic cardiac dysfunction in rat model of angiotensin II-induced hypertension

International Journal of Cardiology

Volumn 167, Issue 2, 2013, Pages 409-415

  Sakamoto, Aiko ^a   Hongo, Makiko ^a   Furuta, Kyoko ^a   Saito, Kan ^a   Nagai, Ryozo ^a   Ishizaka, Nobukazu ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Angiotensin II; Cardiac function; Lipid accumulation; Peroxisome proliferator activated receptor

Indexed keywords

ANGIOTENSIN II; HEME OXYGENASE 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; SUPEROXIDE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DRUG EFFICACY; ENZYME SYNTHESIS; EX VIVO STUDY; GENE EXPRESSION REGULATION; HEART FUNCTION; HEART INJURY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PERFORMANCE; HEART PERFUSION; HISTOLOGY; HYPERTENSION; INTRACELLULAR SIGNALING; IRON STORAGE; LIPID BLOOD LEVEL; LIPID STORAGE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SYSTOLIC DYSFUNCTION; TISSUE LEVEL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; DIASTOLE; DISEASE MODELS, ANIMAL; HEART DISEASES; HYPERTENSION; HYPOGLYCEMIC AGENTS; MALE; RATS; RATS, SPRAGUE-DAWLEY; SYSTOLE; THIAZOLIDINEDIONES;

EID: 84879092835     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.01.007     Document Type: Article

References (42)

1. R.E. Schmieder, K.F. Hilgers, and M.P. Schlaich Renin-angiotensin system and cardiovascular risk Lancet 369 2007 1208 1219
2. K.C. Wollert, and H. Drexler The renin-angiotensin system and experimental heart failure Cardiovasc Res 43 1999 838 849
3. N. Ito, M. Ohishi, and K. Yamamoto Renin-angiotensin inhibition reverses advanced cardiac remodeling in aging spontaneously hypertensive rats Am J Hypertens 20 2007 792 799
4. S. Sciarretta, F. Paneni, and F. Palano Role of the renin-angiotensin- aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction Clin Sci (Lond) 116 2009 467 477
5. Y.T. Zhou, P. Grayburn, and A. Karim Lipotoxic heart disease in obese rats: implications for human obesity Proc Natl Acad Sci U S A 97 2000 1784 1789
6. N.A. van Herpen, and V.B. Schrauwen-Hinderling Lipid accumulation in non-adipose tissue and lipotoxicity Physiol Behav 94 2008 231 241
7. R. Marfella, C. Di Filippo, and M. Portoghese Myocardial lipid accumulation in patients with pressure-overloaded heart and metabolic syndrome J Lipid Res 50 2009 2314 2323
8. T. van de Weijer, V.B. Schrauwen-Hinderling, and P. Schrauwen Lipotoxicity in type 2 diabetic cardiomyopathy Cardiovasc Res 92 2011 10 18
9. J.E. Toblli, G. Cao, and C. Rivas Angiotensin-converting enzyme inhibition reduces lipid deposits in myocardium and improves left ventricular function of obese zucker rats Obesity 14 2006 1586 1595
10. K. Saito, N. Ishizaka, and M. Hara Lipid accumulation and transforming growth factor-beta upregulation in the kidneys of rats administered angiotensin II Hypertension 46 2005 1180 1185
11. M. Hongo, N. Ishizaka, and K. Furuta Administration of angiotensin II, but not catecholamines, induces accumulation of lipids in the rat heart Eur J Pharmacol 604 2009 87 92
12. S. Nemoto, P. Razeghi, and M. Ishiyama PPAR-gamma agonist rosiglitazone ameliorates ventricular dysfunction in experimental chronic mitral regurgitation Am J Physiol Heart Circ Physiol 288 2005 H77 H82
13. N.S. Wayman, Y. Hattori, and M.C. McDonald Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size FASEB J 16 2002 1027 1040
14. A.T. Gonon, A. Bulhak, and F. Labruto Cardioprotection mediated by rosiglitazone, a peroxisome proliferator-activated receptor gamma ligand, in relation to nitric oxide Basic Res Cardiol 102 2007 80 89
15. T. Tsuji, K. Mizushige, and T. Noma Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat J Cardiovasc Pharmacol 38 2001 868 874
16. N. Ishizaka, H. de Leon, and J.B. Laursen Angiotensin II-induced hypertension increases heme oxygenase-1 expression in rat aorta Circulation 96 1997 1923 1929
17. N. Ishizaka, G. Matsuzaki, and K. Saito Expression and localization of PDGF-B, PDGF-D, and PDGF receptor in the kidney of angiotensin II-infused rat Lab Invest 86 2006 1285 1292
18. N. Ishizaka, T. Aizawa, and I. Mori Heme oxygenase-1 is upregulated in the rat heart in response to chronic administration of angiotensin II Am J Physiol Heart Circ Physiol 279 2000 H672 H678
19. T. Aizawa, N. Ishizaka, and J. Taguchi Heme oxygenase-1 is upregulated in the kidney of angiotensin II-induced hypertensive rats: possible role in renoprotection Hypertension 35 2000 800 806
20. N. Ishizaka, K. Saito, and H. Mitani Iron overload augments angiotensin II-induced cardiac fibrosis and promotes neointima formation Circulation 106 2002 1840 1846
21. L.N. Axelsen, J.B. Lademann, and J.S. Petersen Cardiac and metabolic changes in long-term high fructose-fat fed rats with severe obesity and extensive intramyocardial lipid accumulation Am J Physiol Regul Integr Comp Physiol 298 2010 R1560 R1570
22. A.J. Gilde, K.A. van der Lee, and P.H. Willemsen Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism Circ Res 92 2003 518 524
23. A. Nabeebaccus, M. Zhang, and A.M. Shah NADPH oxidases and cardiac remodelling Heart Fail Rev 16 2011 5 12
24. G.Y. Oudit, M.G. Trivieri, and N. Khaper Taurine supplementation reduces oxidative stress and improves cardiovascular function in an iron-overload murine model Circulation 109 2004 1877 1885
25. A.M. van der Kraaij, H.G. van Eijk, and J.F. Koster Prevention of postischemic cardiac injury by the orally active iron chelator 1,2-dimethyl-3-hydroxy-4-pyridone (L1) and the antioxidant (+)-cyanidanol-3 Circulation 80 1989 158 164
26. S. Pucheu, C. Coudray, and N. Tresallet Effect of iron overload in the isolated ischemic and reperfused rat heart Cardiovasc Drugs Ther 7 1993 701 711
27. A. L'Abbate, D. Neglia, and C. Vecoli Beneficial effect of heme oxygenase-1 expression on myocardial ischemia-reperfusion involves an increase in adiponectin in mildly diabetic rats Am J Physiol Heart Circ Physiol 293 2007 H3532 H3541
28. M. Hangaishi, H. Nakajima, and J. Taguchi Lecithinized Cu, Zn-superoxide dismutase limits the infarct size following ischemia-reperfusion injury in rat hearts in vivo Biochem Biophys Res Commun 285 2001 1220 1225
29. X. Liu, J. Wei, and D.H. Peng Absence of heme oxygenase-1 exacerbates myocardial ischemia/reperfusion injury in diabetic mice Diabetes 54 2005 778 784
30. T. Nakamura, E. Yamamoto, and K. Kataoka Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan Hypertension 51 2008 296 301
31. D. Xu, and N. Murakoshi IgarashiM, et al. PPAR-gamma activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model J Cardiovasc Electrophysiol 23 2 2012 Feb 209 217
32. H.C. Yu, S.F. Feng, and P.L. Chao Anti-inflammatory effects of pioglitazone on iron-induced oxidative injury in the nigrostriatal dopaminergic system Neuropathol Appl Neurobiol 36 2010 612 622
33. J. Mersmann, N. Tran, and P.A. Zacharowski Rosiglitazone is cardioprotective in a murine model of myocardial I/R Shock 30 2008 64 68
34. M. Hsu, L. Muchova, and I. Morioka Tissue-specific effects of statins on the expression of heme oxygenase-1 in vivo Biochem Biophys Res Commun 343 2006 738 744
35. N. Grosser, A. Abate, and S. Oberle Heme oxygenase-1 induction may explain the antioxidant profile of aspirin Biochem Biophys Res Commun 308 2003 956 960
36. G. Kronke, A. Kadl, and E. Ikonomu Expression of heme oxygenase-1 in human vascular cells is regulated by peroxisome proliferator-activated receptors Arterioscler Thromb Vasc Biol 27 2007 1276 1282
37. A.M. Wynne, M.M. Mocanu, and D.M. Yellon Pioglitazone mimics preconditioning in the isolated perfused rat heart: a role for the prosurvival kinases PI3K and P42/44MAPK J Cardiovasc Pharmacol 46 2005 817 822
38. L.A. Ahmed, H.A. Salem, and A.S. Attia Pharmacological preconditioning with nicorandil and pioglitazone attenuates myocardial ischemia/reperfusion injury in rats Eur J Pharmacol 663 2011 51 58
39. H. Zhang, A. Zhang, and D.E. Kohan Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione- induced fluid retention Proc Natl Acad Sci U S A 102 2005 9406 9411
40. R.K. Vikramadithyan, K. Hirata, and H. Yagyu Peroxisome proliferator-activated receptor agonists modulate heart function in transgenic mice with lipotoxic cardiomyopathy J Pharmacol Exp Ther 313 2005 586 593
41. L.S. Golfman, C.R. Wilson, and S. Sharma Activation of PPARgamma enhances myocardial glucose oxidation and improves contractile function in isolated working hearts of ZDF rats Am J Physiol Endocrinol Metab 289 2005 E328 E336
42. K. Henriksen, I. Byrjalsen, and P. Qvist Efficacy and safety of the PPARgamma partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy Diabetes Metab Res Rev 27 2011 392 401